热门资讯> 正文
Cencora分销交易提振Citius股价
2025-07-15 20:56
- Citius Pharmaceuticals (NASDAQ:CTXR) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius Oncology (NASDAQ:CTOR), reached a distribution services agreement with the medical distributor Cencora (NYSE:COR) for its lymphoma therapy, Lymphir.
- Under the agreement, Cencora (NYSE:COR) is expected to become a wholesale distributor for Lymphir, an immunotherapy approved by the FDA in August 2024 for adults with relapsed or refractory cutaneous T-cell lymphoma.
- The deal, which builds on an existing distribution services agreement between the two companies, is set to widen Citius Oncology's (NASDAQ:CTOR) commercial distribution network, boosting the drug’s availability upon its market entry in the U.S.
- "As we move closer to the U.S. market introduction of LYMPHIR, we remain focused on disciplined execution across all key commercial readiness activities,” CEO of Citius Pharma (NASDAQ:CTXR) and Citius Oncology (NASDAQ:CTOR) Leonard Mazur remarked.
More on Citius Pharmaceuticals, Cencora, etc.
- Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs
- Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript
- Cencora, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Citius Pharmaceuticals slides on $15.8M securities offering
- Citius Oncology enters distribution services agreement with Cardinal Health
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
